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Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210 S189used in 5 of 6 patients, and was well tolerated. Only 1 of 5
developed citrate gap, which resolved after adjusting citrate
rate. No serious hemorrhagic events were observed. Two of 6
patients died (34%) e Case #1 due to SOS, and #5 due to
systemic CMV infection. These corresponded to the patients
with the highest FO.
Conclusions: 1. Early initiation of CVVH may be a useful
modality to prevent progressive ﬂuid overload and maintain
electrolyte and acid base balance in patients with FO and AKI
following SOS.
2. CVVH with citrate regional anticoagulation is safe and
well tolerated in patients with SOS.SCT Type PRA
(percentage)
Indication for
Treatment
Patient 1 Double umbilical
cord
13 Refractory
thrombocytopenia
without bleed
Patient 2 8/8 HLA matched
peripheral
84 Refractory
thrombocytopenia
with oropharyngeal
bleeding
Patient 3 Double umbilical
cord
100 a. Refractory
thrombocytopenia
with fever
b. Refractory
thrombocytopenia
with GI bleed279
Transplant- Associated Thrombotic Microangiopathy in a
Beta-Thalassemia Major Patient Following Bone Marrow
Transplant- Case Report
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Background: Transplant-associated thrombotic micro-
angiopathy (TA-TMA) is a signiﬁcant complication of he-
matopoietic stem cell transplantation and poses a challenge
with diagnosis and management.
Objectives: To report a case of TA-TMA in an allogeneic bone
marrow transplant (BMT) patient and discuss diagnostic and
management challenges.
Design/Method: Case Report.
Results: Seven year old female with B-thalassemia major
who underwent 10/10 matched unrelated donor BMT. Her
conditioning regimen included Busulfan, Fludarabine,
Cyclophosphamide and ATG, graft versus host disease
(GVHD) prophylaxis included cyclosporin and short course
methotrexate. Post-transplant course was complicated by
grade II acute GVHD, intracranial bleed, GI hemorrhage and
pericardial effusion. She developed several episodes of acute
kidney injury post-transplant with recovery of renal function
back to baseline creatinine (0.3-0.5 mg/dL). Six months post
transplant the patient developed hematuria and worsening
proteinuria followed by intractable hypertension. Renal
function gradually worsened with creatinine rising to w1.6
mg/dL and ended up with oliguria and ﬂuid overload. In
addition she developed hemolytic anemia, thrombocyto-
penia and peripheral blood schistocytes. Several measures
were attempted to improve her renal function including
stopping her calcineurin inhibitor, decreasing her diuretic
regimen and stopping ACE inhibition. Renal biopsy was ob-
tained and showed acute, severe thrombotic micro-
angiopathy. Complement serologies (C3, C4, CFI, CFH levels
and CFH autoantibody) were all normal or elevated. Hemo-
dialysis, therapeutic plasma exchange and basiliximab were
initiated. She received 2 doses of basiliximab and 10 treat-
ments of plasma exchange, resulting in no response. The
patient continued on thrice weekly dialysis. The patient
tolerated dialysis with great difﬁculty complicated by bilat-
eral eye pain, dizziness, extremity tingling and abdominal
pain during her treatments. Finally the patient developed a
syncopal event with mental status changes following one ofher dialysis episodes. EEG conﬁrmed seizure activity. Brain
MRI showed diffuse white matter abnormality consistent
with severe TMA. Given the patient’s progressive worsening
and extreme symptoms, Eculizumab was started. After 3
doses, she has begun to show signs of hematologic recovery
with no signs of renal recovery. Her blood pressure remains
very difﬁcult to control.
Conclusion: TA-TMA is an uncommon but signiﬁcant
complication of HSCT that presents signiﬁcant diagnostic
and management challenges. Even with accurate diagnosis
(clinically and histologically), optimal treatment strategies
remain elusive and the prognosis is poor.
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Allo-Immune Thrombocytopenia
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Introduction: Patients undergoing stem cell transplant
(SCT) for treatment of hematologic malignancies have often
been exposed to many blood products and may be allo-
immunized. This makes platelet transfusions less effective,
which is problematic in patients who are expected to be
profoundly thrombocytopenic for 3-4 weeks. A second-line
intervention in patients with refractory immune thrombo-
cytopenia is continuous intravenous immune globulin (IVIG)
at doses of 1 g/kg/day for 2 days and continuous platelet
transfusion (1 pack of platelets/hour for 72 hours). This
intervention has not been studied in allo-immunized SCT
patients.
Methods: A retrospective chart review was performed at the
University of Wisconsin Hospital to assess outcomes of the
continuous IVIG and platelet regimen in allo-immunized SCT
patients from 1/1/2009 to 12/31/2012. All patients also
received concurrent aminocaproic acid. Data points collected
include primary hematologic diagnosis, indication for treat-
ment, platelet response, clinical bleeding events, requirement
for further therapy, other complications during hospital stay,
and in-hospital mortality.
Results: All of the patients had an increase in platelet count
and therewere no new bleeding events during the treatment
period. The regimen does not appear to provide any long-
standing improvement in platelet response.
Discussion: Continuous IVIG and platelet transfusion does
not appear to decrease allo-reactivity as had been hoped for.
However, it does appear to be safe and does provide a
Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210S190temporary platelet increase. Other means of minimizing risk
for bleeding remain important and include use of amino-
caproic acid and HLA matched platelets, prevention of hy-
pertension while thrombocytopenic, pre-transplant testing
for platelet reactive antibodies so HLA matched platelets
may be obtained sooner, and choice of transplant condi-
tioning regimen.281
Neck Tenderness As an Initial Presentation of
Disseminated Aspergillosis; FNA Is an Option or a Must?
Sherif Badawy. Division of Pediatric Hemtology, Oncology and
Stem Cell Transplant, Ann & Robert H. Lurie Children’s Hospital
of Chicago, Northwestern University Feinberg School of
Medicine, Chicago, IL
Introduction: Asperillus thyroiditis (AT) has been consid-
ered for long time a postmortem diagnosis in immunocom-
promised patients. Disseminated disease is seen in the
majority of patients. Diagnosis of AT during life needs high
index of suspicion.
Objective: We describe an adolescent HSCT recipient with
disseminated aspergillus infection who presented initially
with painful neck swelling and found to have AT.
Case Report: History: A 15 years-old male with history of
Acute Myeloid Leukemia and MUD HSCT who presented to
our institution with painful neck swelling, sore throat, red/
brown sputum and worsening respiratory distress for 2 days.
Mom had of Hashimoto’s thyroiditis. Physical Exam: His had
initial hypotension, tachycardia, tachypnea and ﬁne hand
tremors. He had a neck swelling that was moving up and
down on swallowing with tenderness but no nodules on
palpation. Laboratory: His evaluation showed thrombocyto-
penia, normal WBC counts with neutrophil predominance,
hypokalemia, transaminitis, direct hyperbilirubinemia,
elevated Free T4 and very low TSH. Fine needle aspirate
(FNA) of the thyroid and the sputum showed yeast on KOH.
Imaging: Thyroid US with diffuse heterogeneous enlarge-
ment. CT Chest showed moderate to large areas of pulmo-
nary consolidation bilaterally, with areas of cavitation.
Clinical course: He was started on broad-spectrum antibi-
otics and antifungals. His respiratory and mental status got
worse one day after admission needing transfer of care to the
Pediatric ICU. His FNA of the thyroid grew Aspergillus
Fumigatus. MRI brain showed numerous rounded lesions
consistent with disseminated fungal disease, most likely
Aspergillus. Family chose to continue with palliative care
only with DNR/DNI having his disseminated disease and
critical condition.Discussion: Our patient had evidence of disseminated
invasive aspergillosis involving thyroid, lungs and brain.
Initially he had presumed infectious thyroiditis based on his
clinical examination and laboratory values that were
conﬁrmed to be AT. Thyroid-related symptomatology can be
occasionally seen on presentation. Although viral sub-acute
and bacterial thyroiditis is more common than fungal one,
but in immunocompromised patients AT has to be consid-
ered early on. Thyroid US guided FNA cytology and culture is
considered to be a well-tolerated procedure that frequently
utilized to diagnose AT successfully. Any delay in the man-
agement may signiﬁcantly affect the outcomes where thy-
roid FNA can play a critical role in the early diagnosis of AT.
Conclusion: The diagnosis of Aspergillus Thyroiditis requires
a high index of suspicion and it can be the initial presentation
of disseminated invasive aspergillosis. Further studies are
needed to evaluate the beneﬁts of combined antifungals and
address the management of thyroid hormone dysregulation.282
Low Dose Deﬁbrotide for Management of Hepatic Veno-
Occlusive Disease
Bhausaheb Bagal, Aliya Choughale, Navin Navin Khattry. Tata
Memorial Centre, BMT Unit, ACTREC, Navi Mumbai, India
Background and objective: Hepatic veno-occlusive disease
(VOD) is recognized as one of the common and serious
regimen-related toxicity seen after hematopoietic stem cell
transplantation (HSCT). VOD develops in 10% to 60% of pa-
tients after HSCT, and ranges in severity frommild to a severe
syndrome associated with multiorgan failure and death.
Deﬁbrotide (DF) is the only drug found to be effective in the
management of VOD. A randomised study showed that 25
mg/kg/d was equally effective with lesser toxicity compared
to 40mg/kg/d. DF is prohibitively expensive and availability is
scarce in our country.
Methods: Two hundred and ninety nine patients (166
autologous and 133 allogeneic; 210 male and 89 female) who
underwent HSCT between November 2007 and June 2013
were included in this study. All patients received ursodeox-
ycolic acid as prophylaxis. The diagnosis and severity of VOD
was deﬁned according to Seattle criterion. Risk of develop-
ment of severe VOD was estimated by Bearman model.
Patients who developed VOD were initially treated with
frusemide and analgesia. Patients not responding to above
measures in 36-48 hours were given DF.
Results: Seven patients (2.3%) were diagnosed with VOD at a
median of days +14 post transplant (range 11 to 16 days). All
7 patients were classiﬁed as having moderate VOD. All
